Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Completed 37Recruiting 12Active not recruiting 12Terminated 8Withdrawn 5Unknown 2No longer available 2Approved for marketing 2Suspended 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 5Carcinoma, Hepatocellular 1

Interventions

Docetaxel 11Prednisone 10Leuprolide 10Magnetic Resonance Spectroscopy 9bicalutamide 8Radiotherapy 7Abiraterone Acetate 7Biopsy 6gallium 68 PSMA-11 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Metformin 5Goserelin 5radium Ra 223 dichloride 4enzalutamide 4apalutamide 4Specimen Handling 4Injections 4Androgen Antagonists 4pembrolizumab 3orteronel 3cabazitaxel 3abiraterone 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Pioglitazone 3Paclitaxel 3Exercise 3Brachytherapy 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Prostatic Neoplasms × gallium 68 PSMA-11 × Clear all
NCT06881823 2025-12-29

NeoPSMA

Novartis

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT04243941 2024-03-21

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT05034562 2024-03-07

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT04483414 2023-05-19

68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer

University of Texas Southwestern Medical Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT02810886 2017-08-22

ProsPERo

Jules Bordet Institute

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡